Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Kymera Therapeutics Inc KYMR

Kymera Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. The Company's targeted protein degradation (TPD) platform, which it refers to as Pegasus, allows it to discover highly selective small... see more

Recent & Breaking News (NDAQ:KYMR)

Kymera Therapeutics Appoints Elaine Caughey, MBA, as Chief Business Officer

GlobeNewswire June 21, 2021

Kymera Therapeutics Presents New Preclinical Data for its IRAKIMiD Degrader KT-413 Demonstrating Strong Antitumor Activity as Both Monotherapy and in Combination in MYD88-mutant Lymphoma Models

GlobeNewswire June 21, 2021

Kymera Therapeutics to Present New Data Demonstrating both Single-agent and Combination Regressions in MYD88-mutant Lymphoma Preclinical Models with IRAKIMiD Degrader KT-413 at 16th ICML Meeting

GlobeNewswire June 9, 2021

Kymera Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference

GlobeNewswire June 2, 2021

Kymera Therapeutics Presents New Data Demonstrating Proof-of-Degradation Using Novel Tissue-Restricted E3 Ligase

GlobeNewswire May 26, 2021

Kymera Therapeutics Presents Late-Breaking Preclinical Data on IRAK4 Degrader KT-474 at IMMUNOLOGY2021(TM) Annual Meeting

GlobeNewswire May 10, 2021

Kymera Therapeutics Announces First Quarter 2021 Financial Results and Provides a Business Update

GlobeNewswire May 6, 2021

Kymera Therapeutics Appoints Juliet Williams, PhD, as Senior Vice President, Head of Biology

GlobeNewswire May 5, 2021

Kymera Therapeutics to Present New In Vivo Data Demonstrating the Broad Anti-Inflammatory Activity of its IRAK4 Degrader KT-474 at IMMUNOLOGY2021(TM) Annual Meeting

GlobeNewswire May 3, 2021

Kymera Therapeutics Presents Positive Late-Breaking Data from Non-Interventional Study in Patients with Hidradenitis Suppurativa at the Society for Investigative Dermatology 2021 Annual Meeting

GlobeNewswire May 3, 2021

Kymera Therapeutics Honored by Boston Business Journal as a 2021 Best Places to Work Company

GlobeNewswire April 19, 2021

Kymera Therapeutics Presents Late-Breaking Preclinical Data Highlighting Superiority of Dual-Targeting Activity of IRAKIMiD Degrader KT-413 at AACR Annual Meeting 2021

GlobeNewswire April 10, 2021

Kymera Therapeutics to Present New Results from Non-Interventional Study in Patients with Hidradenitis Suppurativa at the Society for Investigative Dermatology (SID) 2021 Annual Meeting

GlobeNewswire April 9, 2021

Kymera Therapeutics Appoints Elena Ridloff, CFA, to Board of Directors

GlobeNewswire March 16, 2021

Kymera Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides a Business Update

GlobeNewswire March 11, 2021

Kymera Therapeutics Announces First-in-Human Dose in Phase 1 Trial of KT-474, a First-in-Class IRAK4 Protein Degrader to Treat Immune-Inflammatory Diseases

GlobeNewswire March 2, 2021

Kymera Therapeutics to Present at Upcoming March Investor Conferences

GlobeNewswire February 25, 2021

Kymera Therapeutics to Present at Upcoming February Investor Conferences

GlobeNewswire February 4, 2021

Kymera Therapeutics Strengthens Leadership with Key Appointments and Promotions

GlobeNewswire February 3, 2021

Kymera Therapeutics Announces Key 2021 Goals and Milestones to Support its Evolution into a Fully Integrated Degrader Medicines Company

GlobeNewswire January 12, 2021